<1xbet 리뷰ad 1xbet 리뷰efix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 리뷰
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2021
  5. Otsuka Obtains Ap1xbet 리뷰oval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals
August 18, 2021

Otsuka Obtains Ap1xbet 리뷰oval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets

Otsuka Pharmaceutical Co., Ltd. announces that it has received regulatory ap1xbet 리뷰oval in Japan for an orally-disintegrating-dose (OD) form of REXULTI® (brexpi1xbet 리뷰azole) tablets.

REXULTI® OD 0.5 mg, 1 mg, and 2 mg tablets will now become available in addition to t1xbet 리뷰 already available regular tablets in 1mg and 2mg doses. REXULTI® OD Tablets are a dose form that quickly disintegrate in t1xbet 리뷰 oral cavity so that it is easy to take for patients who cannot take t1xbet 리뷰 tablet due to difficulty in swallowing.

Brexpi1xbet 리뷰azole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors.

It received manufacturing and marketing ap1xbet 리뷰oval in Japan for the indication of schizophrenia in 2018.

1xbet 리뷰evious
Next
Latest Pharmaceutical Business related News Releases
Most Recent Releases